Advanced Therapeutics最新文献_第2页

A Narrative Review on Efficacy of Cell- and Tissue-Based Therapies for Diabetic Foot Ulcer 以细胞和组织为基础的治疗糖尿病足溃疡的疗效综述

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-19 DOI: 10.1002/adtp.202400335

Behnaz Niroomand, Ibrahim Mohammadzadeh, Maryam Tabarzad, Elham Mohit

{"title":"A Narrative Review on Efficacy of Cell- and Tissue-Based Therapies for Diabetic Foot Ulcer","authors":"Behnaz Niroomand, Ibrahim Mohammadzadeh, Maryam Tabarzad, Elham Mohit","doi":"10.1002/adtp.202400335","DOIUrl":"https://doi.org/10.1002/adtp.202400335","url":null,"abstract":"Diabetic foot ulcers (DFUs) are complex, making conventional treatments challenging in restoring skin tissue. Stem cell therapy (SCT) and skin replacement therapy (SRT) offer promising solutions by addressing prolonged inflammation, impaired cell proliferation, and reduced extracellular support. Here, based on the origin of cells, SCTs are categorized into embryonic, induced pluripotent, fetal, and adult stem cells (ASCs). Mesenchymal stem cells are among the most employed types of ASCs in clinical trials for treating DFUs. Furthermore, their delivery routes, and stem-cell-derived products are also discussed. However, the lack of phase III/V clinical trials limits their clinical use. SRTs are classified by tissue origin (human or animal) and product cellularity. Clinical trials and systematic reviews indicate that placenta-based grafts (e.g., EpiFix), acellular dermal matrices from human cadaver skin (e.g., DermACell and Graftjacket), and bioengineered cell-based products (e.g., Apligraf and Dermagraft) are the most effective and safe for SRT. Both SCT and SRT are evolving fields with ongoing challenges, including injection barriers, cell reprogramming risks, ethical concerns, foreign body reactions, and a lack of long-term follow-up studies.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 7","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging Therapeutic Strategies for Hearing Loss 新兴的听力损失治疗策略

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-16 DOI: 10.1002/adtp.202500127

Shanying Han, Tian Shen, Weiwei He, Hao Wei, Xiaolong Zhao, Wen Yang, Chuan Bu, Xinghua Tang, Yu Zhao, Jiangang Fan

{"title":"Emerging Therapeutic Strategies for Hearing Loss","authors":"Shanying Han, Tian Shen, Weiwei He, Hao Wei, Xiaolong Zhao, Wen Yang, Chuan Bu, Xinghua Tang, Yu Zhao, Jiangang Fan","doi":"10.1002/adtp.202500127","DOIUrl":"https://doi.org/10.1002/adtp.202500127","url":null,"abstract":"Hearing loss (HL) is a significant global health challenge, affecting billions of people and severely impacting quality of life. While traditional interventions such as hearing aids and cochlear implants mitigate symptoms, they fail to address the underlying causes of HL, especially in cases involving severe damage to hair cells or spiral ganglion neurons. Emerging therapeutic strategies, including biomaterials, nanocarrier drug delivery systems, gene therapy, and extracellular vesicle (EV)-based approaches, have demonstrated significant potential in promoting inner ear regeneration and restoring auditory function. Biomaterials mimic the extracellular matrix to guide inner ear cell regeneration, while nanocarriers and EVs enhance the targeted and sustained delivery of therapeutic agents. Gene therapy offers opportunities to correct genetic mutations, addressing hereditary HL. However, challenges such as the anatomical complexity of the cochlea, the blood-labyrinth barrier, and limited regenerative capacity persist. Future research must focus on scalable, biocompatible, and clinically safe delivery systems to advance the clinical translation of these innovative therapies. This review underscores the potential of integrating these strategies to develop effective and long-lasting treatments for HL.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 7","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202500127","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Issue Information (Adv. Therap. 5/2025)

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-14 DOI: 10.1002/adtp.202570012

引用次数: 0

Antibiotic–Polycationic Peptide Conjugation as an Effective Strategy to Overcome Daptomycin Resistance (Adv. Therap. 5/2025)

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-14 DOI: 10.1002/adtp.202570011

Sari Rasheed, Florian Umstätter, Eric Mühlberg, Barbro Beijer, Tobias Hertlein, Karel D. Klika, Christian Kleist, Julia Werner, Cornelius Domhan, Mara Bingel, Anna Müller, Marvin Rausch, Stefan Zimmermann, Knut Ohlsen, Uwe Haberkorn, Marcus Koch, Markus Bischoff, Tanja Schneider, Rolf Müller, Jennifer Herrmann, Walter Mier, Philipp Uhl

引用次数: 0

Therapeutic Targeting of Osteosarcoma and Lung Metastases in Preclinical Models Using a CD24 Antibody-Drug Conjugate 使用CD24抗体-药物偶联物治疗骨肉瘤和肺转移的临床前模型

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-14 DOI: 10.1002/adtp.202400423

Peng Guo, Yuxuan Li, Jing Huang, Liming Jin, Xing Liu, Dawei He, Marsha A. Moses

{"title":"Therapeutic Targeting of Osteosarcoma and Lung Metastases in Preclinical Models Using a CD24 Antibody-Drug Conjugate","authors":"Peng Guo, Yuxuan Li, Jing Huang, Liming Jin, Xing Liu, Dawei He, Marsha A. Moses","doi":"10.1002/adtp.202400423","DOIUrl":"https://doi.org/10.1002/adtp.202400423","url":null,"abstract":"Pulmonary metastases present a significant clinical challenge in the treatment of osteosarcoma (OS). The current therapeutic landscape for metastatic OS is limited by the lack of effective targeted therapies. Here, the development and preclinical evaluation of a novel CD24 antibody-drug conjugate (ADC) designed for the targeted ablation of primary OS tumors and pulmonary metastases are reported. An unbiased, quantitative screening of cancer-related cell surface markers on human OS cells identifies CD24 as a novel target for ADC therapy in OS, owing to its disease-specific overexpression and rapid antigen-mediated internalization. Based on these findings, a proof-of-concept ADC, comprising a humanized CD24 antibody conjugated with mertansine (CD24-DM1), was designed and constructed. CD24-DM1 demonstrated potent cytotoxicity against a panel of human OS cell lines while sparing normal human osteoblasts. In an orthotopic OS model, CD24-DM1 induced complete and durable tumor regression. Additionally, CD24-DM1 significantly delayed tumor growth in a lung-metastatic OS model, providing robust in vivo evidence of CD24 as a promising ADC target for OS therapy. In conclusion, CD24-DM1 exhibits a favorable therapeutic index for the treatment of metastatic OS in preclinical models, highlighting its potential as an effective targeted therapeutic option.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144308849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing the Potential of Stimuli-Responsive Double-Network DNA Hydrogels Toward Nanotheranostics 利用刺激反应双网络DNA水凝胶在纳米治疗中的潜力

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-10 DOI: 10.1002/adtp.202500036

Kishika Arora, Shikha Awasthi

{"title":"Harnessing the Potential of Stimuli-Responsive Double-Network DNA Hydrogels Toward Nanotheranostics","authors":"Kishika Arora, Shikha Awasthi","doi":"10.1002/adtp.202500036","DOIUrl":"https://doi.org/10.1002/adtp.202500036","url":null,"abstract":"The convergence of hydrogel science and Deoxyribonucleic acid (DNA) nanotechnology has led to the development of an innovative category of materials: double-network (DN) DNA hydrogels. These hydrogels are gaining consequential attention because they show advanced responsiveness toward functional stimuli, thus revealing their remarkable potential in therapeutics. This review comprehensively examines the different strategies for synthesizing double-network (DN) DNA hydrogels, delving into their classification based on their response to biological and nonbiological stimuli. This highlights the innovative methodologies that enable the design of these hybrid hydrogels, which guarantee high-toughness and low-cost materials. This review also reports certain recent studies on these hydrogels, emphasizing the intricate relationship between the structure and performance of DN DNA hydrogels and confirming their tailored mechanical properties achieved through programmable DNA sequences and versatile ligation techniques. This report not only provides an overview of the mechanical properties of DNA hydrogels from a synthetic standpoint for various applications but also discusses methods for regulating these properties. Therefore, this report anticipates that readers will procure an ample portrayal of innovative synthesis techniques, diverse classifications, and promising applications of DN-DNA hydrogels, offering a roadmap for future research and development in this transformative area of materials science.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 7","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted Oral Delivery of Exosomal Formulation of Cannabidiol against Lung Cancer 靶向口服大麻二酚外泌体制剂治疗肺癌

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-09 DOI: 10.1002/adtp.202400362

Disha Nagesh Moholkar, Raghuram Kandimalla, Jeyaprakash Jeyabalan, Jun Yan, Zhao-Hui Song, Farrukh Aqil, Ramesh C. Gupta

{"title":"Targeted Oral Delivery of Exosomal Formulation of Cannabidiol against Lung Cancer","authors":"Disha Nagesh Moholkar, Raghuram Kandimalla, Jeyaprakash Jeyabalan, Jun Yan, Zhao-Hui Song, Farrukh Aqil, Ramesh C. Gupta","doi":"10.1002/adtp.202400362","DOIUrl":"https://doi.org/10.1002/adtp.202400362","url":null,"abstract":"Despite advances in the treatment of lung cancer, the survival rate remains low due to lack of specificity and selectivity. The use of appropriate nano-drug delivery vehicle can overcome these issues. Cannabidiol (CBD) has the potential to be used as a novel therapeutic agent for treating cancer. The study utilizes colostrum-derived exosomes as nano-carriers for the delivery of CBD to overcome its low oral bioavailability. Exosomes are isolated from colostrum powder by sequential ultracentrifugation. Following CBD loading the formulations (ExoCBD and FA-ExoCBD) are characterized for their physical parameters (size, charge, and zeta potential). Cell culture assays (MTT, colony forming) are performed to analyze the anti-cancer activity of CBD and ExoCBD against drug-sensitive and resistant lung cancer cells and followed by orthotopic lung tumor xenograft mouse-model. FA-functionalized exosomal formulation of CBD provides a drug load of 20–24%. CBD and its exosomal formulations show antiproliferative and anti-inflammatory activities against both lung cancer cells and reduce the colony forming ability. Mechanistically, CBD decreased the expression of CB2, cell cycle markers, NF-κB, and IκBα, while increasing GPR3 levels in both drug-sensitive and drug-resistant lung cancer cells, as well as MDR-1 in drug-resistant cells. Orally administered FA-ExoCBD shows superior tumor growth inhibition as compared to free CBD (80% vs 60%) at one-half the dose of 7.5 mg kg−1 versus 15 mg kg−1. FA-ExoCBD can be developed as a potential targeted oral drug in the quest of lung cancer management.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 7","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synthetic Mucus Biomaterials Synergize with Antibiofilm Agents to Combat Pseudomonas aeruginosa Biofilms 合成黏液生物材料与抗菌膜剂协同对抗铜绿假单胞菌生物膜

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-04-29 DOI: 10.1002/adtp.202400359

Sydney Yang, Allison Boboltz, Alexa Stern, Vaidehi Rathi, Gregg Duncan

{"title":"Synthetic Mucus Biomaterials Synergize with Antibiofilm Agents to Combat Pseudomonas aeruginosa Biofilms","authors":"Sydney Yang, Allison Boboltz, Alexa Stern, Vaidehi Rathi, Gregg Duncan","doi":"10.1002/adtp.202400359","DOIUrl":"https://doi.org/10.1002/adtp.202400359","url":null,"abstract":"Bacterial biofilms are often highly resistant to antimicrobials causing persistent infections which, when not effectively managed, can significantly worsen clinical outcomes. As such, alternatives to standard antibiotic therapies have been highly sought after to address difficult-to-treat biofilm-associated infections. A biomaterial-based approach using the innate functions of mucins is hypothesized to modulate bacterial surface attachment and virulence can provide a new therapeutic strategy against biofilms. Based on the testing in Pseudomonas aeruginosa biofilms, it is found that synthetic mucus biomaterials can inhibit biofilm formation and significantly reduce the thickness of mature biofilms. In addition, if synthetic mucus biomaterials can work synergistically with DNase and/or α-amylase for enhanced biofilm dispersal is evaluated. Combination treatment with these antibiofilm agents and synthetic mucus biomaterials resulted in up to 2 log reductions in the viability of mature P. aeruginosa biofilms. Overall, this work provides a new bio-inspired, combinatorial approach to address biofilms and antibiotic-resistant bacterial infections.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400359","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mimicking Biochemical Traits with a Synthetic Lipid Nanoparticles SARS-COV-2 Model 用合成脂质纳米颗粒模拟SARS-COV-2模型的生化特性

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-04-28 DOI: 10.1002/adtp.202400401

Ignasia Handipta Mahardika, Hyun Park, Eunjin Huh, Changyoon Baek, Shin-Gyu Cho, Kwang-Hwan Jung, Junhong Min, Kwanwoo Shin

{"title":"Mimicking Biochemical Traits with a Synthetic Lipid Nanoparticles SARS-COV-2 Model","authors":"Ignasia Handipta Mahardika, Hyun Park, Eunjin Huh, Changyoon Baek, Shin-Gyu Cho, Kwang-Hwan Jung, Junhong Min, Kwanwoo Shin","doi":"10.1002/adtp.202400401","DOIUrl":"https://doi.org/10.1002/adtp.202400401","url":null,"abstract":"The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the global pandemic challenges diagnostic technologies, underscoring the urgent need for quick adaptation and innovation to improve accuracy and efficiency against new variants. The study introduces a synthetic Lipid Nanoparticles (LNPs) model of SARS-CoV-2, utilizing advancements in LNPs vaccine technology to mimic the virus's key biochemical and genetic traits. This liposomal model encapsulates the characteristic SARS-CoV-2 mRNA and nucleocapsid (N) proteins within LNPs and further conjugates with spike (S) protein derivatives on its outer membrane, closely replicating the virus's structure and inducing accurate antigen-antibody responses in diagnostic tests. Furthermore, validation using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) with commercial SARS-CoV-2 reagents confirms its effectiveness in simulating viral RNA amplification. This establishes it as an efficient tool for assessing the diagnostic efficacy of newly marketed diagnostic products. This LNPs model represents a significant advancement in diagnostic development, offering potential for therapeutic and vaccine research while ensuring safety and scalability.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400401","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoparticles Combining Host-Directed Therapeutics and Antibiotics to Boost Bacterial Killing and Overall Survival of Zebrafish Embryos Infected with Mycobacterium Marinum (Adv. Therap. 4/2025) 结合宿主导向疗法和抗生素的纳米颗粒提高感染海洋分枝杆菌的斑马鱼胚胎的细菌杀伤和总体存活率（ad . therapp . 4/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-04-18 DOI: 10.1002/adtp.202570009

Gabriela Schäfer, Dongdong Bi, Federico Fenaroli, Andrew M. Thompson, Anno Saris, Matthias Barz

引用次数: 0